title: Could oral spleen tyrosine kinase inhibitors lead to neoplastic transformation?
authors.forename: Sujoy
authors.initials: S
authors.lastname: Khan
authors.forename: Philip C
authors.initials: PC
authors.lastname: Doré
authors.forename: W A C
authors.initials: WA
authors.lastname: Sewell
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000187:drug effects; D013154:Spleen / Q000187:drug effects / Q000201:enzymology*; D000072377:Syk Kinase
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase